Three recent clinical updates illustrate the opportunities and challenges facing next-generation oncology therapies. ADC Therapeutics reported positive efficacy data for Zynlonta...

EyesOn Strategic Agility in Action: How Biopharma Companies Are Managing Clinical, Commercial, and Operational Levers to Sustain Growth

EyesOn Pharma posts will continue during the period. Cheers, The PharmaTell Team.

Business Development as a Strategic Lever: Looking at how Biopharma Companies are tapping into a mix of Acquisitions, Licensing, and Partnerships to Reposition for Growth

Pharma Phriday (June 12, 2026). Oral drug delivery continued to reshape the obesity and HIV treatment landscapes. AI platform deals deepened beyond pilots into multi-year operational commitments. BD&L activity was substantial, spanning late-stage acquisitions, platform licensing, and preclinical bets. Regulatory milestones touched rare disease, oncology, and haematology. Several long-standing therapeutic hypotheses were either validated or refuted by Phase III data.

A landmark week across oncology, with pivotal data in lung, prostate, bladder, and haematological cancers reshaping treatment paradigms in both early and advanced disease. Gene editing, RNA therapeutics, and AI drug discovery attracted major capital commitments. Kidney disease emerged as a strategic battleground. A persistent US drug pricing gap versus other high-income countries remained unresolved.